Velleca named CEO of G1 Therapeutics
"I'm honored and excited to be joining G1 at such a pivotal time for the company," Velleca said. "With its novel CDK4/6 platform, G1 has the potential to fulfill significant unmet needs for cancer patients. I look forward to working closely with G1's talented and seasoned team, including its founders, board, investors, and scientists, to successfully grow the company and advance its pipeline of innovative therapeutics."
Velleca was previously instrumental in the founding, building and leading of CGI Pharmaceuticals until its 2010 acquisition by Gilead Sciences. He served most recently as the executive vice president at The Leukemia & Lymphoma Society.
"We are delighted to welcome Mark to G1 as our CEO," Seth Rudnick, the chairman of G1's board of directors, said. "The combination of Mark's well-established relationships with the oncology community and his background as a board-certified physician, scientist and industry executive make him an ideal leader for G1 as we prepare to advance our lead product candidate for chemotherapy-induced myelosuppression to IND status this summer and explore additional oncology opportunities for our novel kinase inhibitors."
Velleca earned a B.S. in biology cum laude from Yale University and an M.D. and Ph.D. in neuroscience from Washington University in St. Louis.